CBIO
Crescent Biopharma
CBIO
CBIO
54 hedge funds and large institutions have $46.6M invested in Crescent Biopharma in 2023 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 13 increasing their positions, 10 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
0.05% more ownership
Funds ownership: 0.52% → 0.58% (+0.05%)
44% less capital invested
Capital invested by funds: $83.1M → $46.6M (-$36.5M)
Holders
54
Holding in Top 10
–
Calls
$721K
Puts
$607K
Top Buyers
| 1 | +$10.8M | |
| 2 | +$3.78M | |
| 3 | +$2.03M | |
| 4 |
Goldman Sachs
New York
|
+$1.05M |
| 5 |
Two Sigma Advisers
New York
|
+$507K |
Top Sellers
| 1 | -$5.3M | |
| 2 | -$952K | |
| 3 | -$682K | |
| 4 |
Millennium Management
New York
|
-$546K |
| 5 |
EP
Eversept Partners
New York
|
-$305K |